The FDA's expanded approval of FILSPARI is the first targeted therapy for a serious progressive kidney disorder — and it signals a wider opening for the entire rare nephrology space. When one company breaks through, the whole sector gains momentum.
Treatments for rare conditions often earn premium pricing and long periods of market exclusivity — meaning companies that crack these indications can generate outsized returns. Analysts are watching this space very closely right now.
This group was built by professional analysts in direct response to a major regulatory catalyst, blending high-growth biotech innovation with established kidney care providers. Missing this window could mean missing the early momentum.
This basket's total market capitalisation is $29.28B, with a clear concentration in larger-cap holdings. That large-cap dominance generally anchors the basket, tending to lower volatility and produce a more stable return profile.
DVA: $10.12B
TVTX: $2.84B
AUPH: $2.14B
The FDA's expanded approval of Travere's FILSPARI for a rare kidney disorder has sparked fresh momentum across the nephrology space. This group is built around the idea that rare kidney conditions represent a fast-growing, underserved market — one where successful treatments can command premium pricing and long periods of exclusivity. From cutting-edge clinical-stage biotechs to established dialysis providers, these companies sit at the forefront of a shifting treatment landscape.
This group blends two distinct types of companies: high-growth, clinical-stage biotechnology firms developing novel therapies for conditions like lupus nephritis and polycystic kidney disease, and established healthcare providers delivering essential dialysis services. That mix means you get exposure to both innovation-driven upside and more defensive, specialised healthcare operations — making it a varied but focused thematic allocation.
Each stock in this group was handpicked by professional analysts in direct response to Travere's landmark regulatory win. The selection captures companies across the kidney care value chain — those pioneering orphan drug approvals, those targeting rare renal conditions with novel mechanisms, and those providing life-sustaining care. These are not random picks; they reflect deliberate, insight-driven curation built around a clear and timely catalyst.
The FDA's expanded approval of Travere's FILSPARI validates the growing market for rare nephrology treatments. This milestone creates positive momentum for biopharma companies developing innovative therapies for underserved kidney conditions.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Published on April 14
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+4
Here are a few of the assets in this group. Create an account to unlock the full list.
On average, analysts expect assets in this group to grow 78.14% over the next year.
7 of 13 assets in this group are rated Buy by professional analysts.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+78.14%
